Sugi Predict

Sugi Predict / Compounds / SCHEMBL1732540

SCHEMBL1732540

SCHEMBL1732540

CC(=O)NC(Cc1ccccc1)C(=O)NC(Cc1ccc(N2CC(=O)NS2(=O)=O)cc1)C(=O)NCCc1ccc(CC(=O)O)cc1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 3/20 0.42
▸ CTSS P25774 1/20 0.42
▸ CTSK P43235 1/20 0.42
▸ CTSL P07711 2/20 0.41
▸ SRC P12931 1/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ MMP8 P22894 2/20 0.39
▸ GNPAT O15228 1/20 0.38
▸ PSMB1 P20618 1/20 0.38
▸ PSMB5 P28074 1/20 0.38
▸ PSMB2 P49721 1/20 0.38
▸ OPRM1 P35372 1/20 0.38
▸ MMP2 P08253 2/20 0.37
▸ MMP9 P14780 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1731839 1.00 PTPN1 (0.42) PTPN1CTSSCTSKCTSLSRC
SCHEMBL12151807 0.94 PTPN1 (0.41) PTPN1CTSSCTSLKMT2AMMP8
SCHEMBL1730696 0.90 SRC (0.47) PTPN1CTSSCTSKCTSLSRC
SCHEMBL1732507 0.90 SRC (0.47) PTPN1CTSSCTSKCTSLSRC
SCHEMBL2184299 0.87 PTPN1 (0.52) PTPN1CTSSCTSKKMT2A
SCHEMBL1731562 0.87 PTPN1 (0.52) PTPN1CTSSCTSKKMT2A
SCHEMBL1731564 0.87 PTPN1 (0.52) PTPN1CTSSCTSKKMT2A
SCHEMBL6141374 0.80 LCK (0.47) PTPN1CTSLSRCKMT2APSMB1
SCHEMBL2186575 0.80 PTPN1 (0.50) PTPN1KMT2A
SCHEMBL1732891 0.80 PTPN1 (0.50) PTPN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1492780-B1 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS NOVARTIS AG (CH) 2011-11-23 — — EP claimed
US-20080139576-A1 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives NOVARTIS AG (CH) 2008-06-12 — — US claimed
US-7291635-B2 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives NOVARTIS AG (CH) 2007-11-06 — — US claimed
US-20050090502-A1 Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents NOVARTIS AG (CH) 2005-04-28 — — US claimed
US-20040023974-A1 Cyclic sulfamide derivatives and methods of use COPPOLA GARY MARK 2004-02-05 — — US claimed
EP-1492780-B1 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS NOVARTIS AG (CH) 2011-11-23 — — EP disclosed
US-20040023974-A1 Cyclic sulfamide derivatives and methods of use COPPOLA GARY MARK 2004-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139576-A1 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives PTPRS, PTPRJ, IRS1 PTPN1 10/4885CTSS 1794/4885CTSK 3257/4885
US-20050090502-A1 Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents PTPRS, PTPMT1, PTPN1 PTPN1 3/4885CTSS 1393/4885CTSK 2965/4885
US-20040023974-A1 Cyclic sulfamide derivatives and methods of use PTPRS, PTPA, PTPMT1 PTPN1 9/4885CTSS 697/4885CTSK 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.